• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by PTC Therapeutics Inc.

    10/30/25 3:49:09 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTCT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 10)


    PTC Therapeutics Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    69366J200

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    69366J200


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    530,520.00
    7Sole Dispositive Power

    7,661,315.00
    8Shared Dispositive Power

    627,684.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,288,999.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.43 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PTC Therapeutics Inc
    (b)Address of issuer's principal executive offices:

    100 Corporate Court, South Plainfield, NJ, 07080
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    69366J200
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    8288999
    (b)Percent of class:

    10.43  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    530520

     (iii) Sole power to dispose or to direct the disposition of:

    7661315

     (iv) Shared power to dispose or to direct the disposition of:

    627684

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:10/30/2025
    Get the next $PTCT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTCT

    DatePrice TargetRatingAnalyst
    10/20/2025$73.00Overweight
    Wells Fargo
    6/17/2025$80.00Buy
    Truist
    5/9/2025$68.00Neutral → Buy
    BofA Securities
    5/7/2025$40.00Sell → Neutral
    Citigroup
    3/11/2025$41.00 → $55.00Underperform → Neutral
    BofA Securities
    3/7/2025$55.00Sector Perform
    Scotiabank
    12/13/2024$45.00 → $67.00Equal-Weight → Overweight
    Morgan Stanley
    12/3/2024$39.00 → $63.00Sector Perform → Outperform
    RBC Capital Mkts
    More analyst ratings

    $PTCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gravier Pierre bought $198,736 worth of shares (7,700 units at $25.81), increasing direct ownership by 30% to 33,700 units (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    12/14/23 4:38:32 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Reeve Emma sold $1,088,787 worth of shares (15,666 units at $69.50) and exercised 12,000 shares at a strike of $38.10, decreasing direct ownership by 35% to 6,666 units (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    10/31/25 5:20:05 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EXEC. VP AND CLO Boulding Mark Elliott exercised 3,375 shares at a strike of $38.10 and sold $214,091 worth of shares (3,375 units at $63.43) (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    10/9/25 5:20:05 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Reeve Emma exercised 25,562 shares at a strike of $35.73 and sold $1,686,024 worth of shares (25,562 units at $65.96) (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    10/7/25 5:20:15 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $PTCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

    – Initiated US and EU launch of Sephience™ (sepiapterin) –  – Strong initial Sephience uptake with global revenue of $19.6M and 521 start forms in the US as of September 30 – – Robust Q3 performance with total revenue of $211M – – Full-year 2025 revenue guidance narrowed to $750 - $800M – WARREN, N.J., Nov. 4, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the third quarter ended September 30, 2025.  "We achieved an outstanding quarter, highlighted by the strong start to the global Sephience launch," said Matthew B. Klein, M.D., Chief Executive Officer. "The broad initial uptake supports the potential of Sephience to b

    11/4/25 4:01:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics to Participate at Upcoming Investor Conferences

    WARREN, N.J., Oct. 31, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that its executives will speak at the following conferences: UBS Global Healthcare Conference 2025Tuesday, Nov. 11 at 3:30 p.m. EST Jefferies Global Healthcare Conference 2025Tuesday, Nov. 18 at 8 a.m. GMT / 3:00 a.m. EST Citi 2025 Global Healthcare ConferenceThursday, Dec. 4 at 10:30 a.m. EST The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be a

    10/31/25 8:00:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WARREN, N.J., Oct. 27, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on Oct. 23, 2025, the company approved non-statutory stock options to purchase an aggregate of 2,000 shares of its common stock and 1,990 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to two new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on Oct.

    10/27/25 4:30:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    SEC Filings

    View All

    SEC Form 10-Q filed by PTC Therapeutics Inc.

    10-Q - PTC THERAPEUTICS, INC. (0001070081) (Filer)

    11/4/25 4:33:24 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)

    11/4/25 4:10:14 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by PTC Therapeutics Inc.

    SCHEDULE 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    10/30/25 3:49:09 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on PTC Therapeutics with a new price target

    Wells Fargo initiated coverage of PTC Therapeutics with a rating of Overweight and set a new price target of $73.00

    10/20/25 8:02:41 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on PTC Therapeutics with a new price target

    Truist initiated coverage of PTC Therapeutics with a rating of Buy and set a new price target of $80.00

    6/17/25 7:50:47 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics upgraded by BofA Securities with a new price target

    BofA Securities upgraded PTC Therapeutics from Neutral to Buy and set a new price target of $68.00

    5/9/25 8:40:13 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Leadership Updates

    Live Leadership Updates

    View All

    Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

    BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. "We are excited to welcome David to our Board," said Dick Simon, Chief Executive Officer of Sensorium. "He is a seasoned life sciences executive with a track record of success that spans multiple therapeutic areas and development stages. David's depth of experience will be a key asset as we advance our lead program, SENS-01, towards the clinic and expand our drug pipeline into addition

    9/12/23 8:00:00 AM ET
    $PTCT
    $SPRO
    $TCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer

    SOUTH PLAINFIELD, N.J., July 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced the appointment of Pierre Gravier to the role of Chief Financial Officer (CFO). Mr. Gravier brings more than 17 years of experience as an investment banker, venture capitalist and scientist to PTC. Most recently, Pierre was a managing director in the healthcare group of Perella Weinberg Partners, a leading independent global advisory firm. At Perella Weinberg, he focused on advising companies in the biopharmaceutical and pharmaceutical sectors on finance strategy and corporate development. "We are incredibly excited to have Pierre as part of PTC's leadership team," said Matthew B. Klein

    7/17/23 4:30:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Financials

    Live finance-specific insights

    View All

    PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

    – Initiated US and EU launch of Sephience™ (sepiapterin) –  – Strong initial Sephience uptake with global revenue of $19.6M and 521 start forms in the US as of September 30 – – Robust Q3 performance with total revenue of $211M – – Full-year 2025 revenue guidance narrowed to $750 - $800M – WARREN, N.J., Nov. 4, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the third quarter ended September 30, 2025.  "We achieved an outstanding quarter, highlighted by the strong start to the global Sephience launch," said Matthew B. Klein, M.D., Chief Executive Officer. "The broad initial uptake supports the potential of Sephience to b

    11/4/25 4:01:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results

    WARREN, N.J., Oct. 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its third quarter 2025 financial results and provide an update on the company's business and outlook on Tuesday, November 4, at 4:30 p.m. ET. To access the call by phone, please click here to register, and you will be provided with dial-in details. To avoid delays, we recommend that participants dial in for the conference call 15 minutes before the start of the call. The webcast conference call can be accessed on the In

    10/21/25 8:00:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    – European and FDA approval of Sephience™ (sepiapterin) with broad labeling for PKU – – Global launch underway in Europe and U.S. – – Total Q2 Revenue of $179M – WARREN, N.J., Aug. 7, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the second quarter ended June 30, 2025.  "We had another strong quarter highlighted by the first approvals of Sephience for the treatment of children and adults with PKU," said Matthew B. Klein, M.D., Chief Executive Officer. "We have initiated the global launch and expect Sephience to be the foundational product for PTC's future growth and path to profitability." Key Corporate Updates:  Sec

    8/7/25 4:01:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

    SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    11/14/24 5:22:11 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

    SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    11/8/24 10:52:39 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

    SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    10/18/24 10:57:11 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care